ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v14i4.1760ppharm-1537Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTОпыт вакцинации 13-валентной конъюгированной пневмококковой вакциной пациентки с ювенильным идиопатическим артритом с частыми респираторными инфекциями на фоне терапии метотрексатомThe Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapyhttps://orcid.org/0000-0002-6150-0880СолошенкоМ. А.SoloshenkoMargarita A.https://orcid.org/0000-0002-3874-4721АлексееваЕ. И.AlekseevaEkaterina I.

доктор медицинских наук, профессор, член-корреспондент РАН, заведующая ревматологическим отделением НМИЦ здоровья детей, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-02-97

alekatya@yandex.ruДворяковскаяТ. М.DvoryakovskayaТatyana M.ИсаеваК. Б.IsaevaKsenia B.МаянскийН. А.MayanskyNikolay A.ТкаченкоН. Е.TkachenkoNatalya E.ЗубковаИ. В.ZubkovaIrina V.НовиковаД. А.NovikovaDarya A.КалюжнаяТ. А.KalyuzhnayaТatyana A.ШахтахтинскаяФ. Ч.ShakhtakhtinskayaFiruza Ch.ГайворонскаяА. Г.GayvoronskayaAnna G.https://orcid.org/0000-0002-4669-9510БроеваМ. И.BroevаMarika I.ФедосеенкоМ. В.FedoseenkoМarina V.Национальный научно-практический центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНациональный научно-практический центр здоровья детей Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияNational Medical Research Center of Children’s Health I.M. Sechenov First Moscow State Medical UniversityRussian Federation201705102017144287293Copyright © Солошенко М.А., Алексеева Е.И., Дворяковская Т.М., Исаева К.Б., Маянский Н.А., Ткаченко Н.Е., Зубкова И.В., Новикова Д.А., Калюжная Т.А., Шахтахтинская Ф.Ч., Гайворонская А.Г., Броева М.И., Федосеенко М.В., 20172017Солошенко М.А., Алексеева Е.И., Дворяковская Т.М., Исаева К.Б., Маянский Н.А., Ткаченко Н.Е., Зубкова И.В., Новикова Д.А., Калюжная Т.А., Шахтахтинская Ф.Ч., Гайворонская А.Г., Броева М.И., Федосеенко М.В.Soloshenko M.A., Alekseeva E.I., Dvoryakovskaya Т.M., Isaeva K.B., Mayansky N.A., Tkachenko N.E., Zubkova I.V., Novikova D.A., Kalyuzhnaya Т.A., Shakhtakhtinskaya F.C., Gayvoronskaya A.G., Broevа M.I., Fedoseenko М.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1537

Представлен опыт вакцинации 13-валентной конъюгированной пневмококковой вакциной (13ПКВ) пациентки в возрасте 5 лет с олигоартикулярным ювенильным идиопатическим артритом (ЮИА), получавшей метотрексат в дозе 15 мг/м2 в неделю подкожно. Лечение метотрексатом обеспечило ремиссию ЮИА, но сопровождалось частыми респираторными инфекциями — до 8 раз в год. При развитии инфекций инъекции метотрексата пропускались. Перерывы в лечении метотрексатом сопровождались обострением основного заболевания. Вакцинация пациентки 13ПКВ обеспечила снижение частоты респираторных инфекций до 2 раз в год, что сопровождалось развитием стойкой ремиссии заболевания. Нежелательных явлений и обострения ЮИА у ребенка на фоне вакцинации 13ПКВ не зарегистрировано.

The article presents the experience of vaccination with a pneumococcal 13-valent conjugate vaccine (PCV13) of a patient aged 5 years with oligoarticular juvenile idiopathic arthritis (JIA) receiving methotrexate at a dose of 15 mg/m2 per week subcutaneously. Treatment with methotrexate provided a remission of JIA, but was accompanied by frequent respiratory infections — up to 8 times a year. During infection progression, methotrexate injections were omitted. Gaps in the treatment with methotrexate were accompanied by an exacerbation of the underlying condition. Vaccination of the patient with PCV13 reduced the frequency of respiratory infections to 2 times a year, which was accompanied by the development of persistent remission of the disease. Adverse events and exacerbation of JIA in a child after vaccination with PCV13 were not registered.

детиювенильный идиопатический артритметотрексатвакцинация13-валентная конъюгированная пневмококковая вакцинаchildrenjuvenile idiopathic arthritismethotrexatevaccinationpneumococcal 13-valent conjugate vaccineReferencesАлексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.: ВЕДИ; 2007. — 368 с. [Alexeeva EI, Litvitskii PF, Baranov AA. Yuvenil’nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).]Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. А.А. Баранова. — М.: ВЕДИ; 2007. — 368 с. [Alexeeva EI, Litvitskii PF, Baranov AA. Yuvenil’nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).]Алексеева Е.И. Ювенильный идиопатический артрит: клиническая картина, диагностика, лечение // Вопросы современной педиатрии. — 2015. — Т.14. — №1 — С. 78–94. [Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current pediatrics. 2015;14(1):78–94. (In Russ).] doi: 10.15690/vsp.v14i1.1266.Алексеева Е.И. Ювенильный идиопатический артрит: клиническая картина, диагностика, лечение // Вопросы современной педиатрии. — 2015. — Т.14. — №1 — С. 78–94. [Alexeeva EI. Juvenile idiopathic arthritis: clinical picture, diagnosis, treatment. Current pediatrics. 2015;14(1):78–94. (In Russ).] doi: 10.15690/vsp.v14i1.1266.Hurd A, Beukelman T. Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep. 2013;15(5):327. doi: 10.1007/s11926-013-0327-1.Hurd A, Beukelman T. Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep. 2013;15(5):327. doi: 10.1007/s11926-013-0327-1.Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.Баранов А.А., Алексеева Е.И., Бзарова Т.М., и др. Протокол ведения пациентов с ювенильным артритом // Вопросы современной педиатрии. — 2013. — Т.12. — №1 — С. 37–56. [Baranov AA,Alexeeva EI, Bzarova TM, et al. Management protocol for patients with juvenile arthritis. Current pediatrics. 2013;12(1):37–56. (In Russ.)] doi: 10.15690/vsp.v12i1.557.Баранов А.А., Алексеева Е.И., Бзарова Т.М., и др. Протокол ведения пациентов с ювенильным артритом // Вопросы современной педиатрии. — 2013. — Т.12. — №1 — С. 37–56. [Baranov AA,Alexeeva EI, Bzarova TM, et al. Management protocol for patients with juvenile arthritis. Current pediatrics. 2013;12(1):37–56. (In Russ.)] doi: 10.15690/vsp.v12i1.557.Алексеева Е.И., Слепцова Т.В., Валиева С.И., и др. Ретроспективный анализ эффективности и безопасности метотрексата для подкожного введения у больных ювенильным идиопатическим артритом // Вопросы современной педиатрии. — 2013. — Т.12. — №4 — С. 38–46. [Alexeeva EI, Sleptsova TV, Valieva SI, et al. Retrospective analysis of efficacy and safety of hypodermic methotrexate injections in patients with juvenile idiopathic arthritis. Current pediatrics. 2013;12(4):38–46. (In Russ).] doi: 10.15690/vsp.v12i4.729.Алексеева Е.И., Слепцова Т.В., Валиева С.И., и др. Ретроспективный анализ эффективности и безопасности метотрексата для подкожного введения у больных ювенильным идиопатическим артритом // Вопросы современной педиатрии. — 2013. — Т.12. — №4 — С. 38–46. [Alexeeva EI, Sleptsova TV, Valieva SI, et al. Retrospective analysis of efficacy and safety of hypodermic methotrexate injections in patients with juvenile idiopathic arthritis. Current pediatrics. 2013;12(4):38–46. (In Russ).] doi: 10.15690/vsp.v12i4.729.Klein A, Kaul I, Foeldvari I, et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: An observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349– 1356. doi: 10.1002/acr.21697.Klein A, Kaul I, Foeldvari I, et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: An observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349– 1356. doi: 10.1002/acr.21697.Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88(3):197–200. doi: 10.1136/adc.88.3.197.Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88(3):197–200. doi: 10.1136/adc.88.3.197.Бзарова ТМ., Алексеева ЕИ., Петеркова ВА. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом // Вопросы современной педиатрии. — 2006. — Т.5. — №5 — С. 13–18. [Bzarova TM, Aleksyeva EI, Peterkova VA. The impact of disease and antirheumatic therapy factors on growth retardation in children suffering from juvenile rheumatoid arthritis. Current pediatrics. 2006;5(5):13–18 (In Russ).]Бзарова ТМ., Алексеева ЕИ., Петеркова ВА. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом // Вопросы современной педиатрии. — 2006. — Т.5. — №5 — С. 13–18. [Bzarova TM, Aleksyeva EI, Peterkova VA. The impact of disease and antirheumatic therapy factors on growth retardation in children suffering from juvenile rheumatoid arthritis. Current pediatrics. 2006;5(5):13–18 (In Russ).]Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639. doi: 10.1002/acr.21641.Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–639. doi: 10.1002/acr.21641.Berntson L, Fasth A, Andersson-Gare B, et al. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol. 2001;28(12):2737–2743.Berntson L, Fasth A, Andersson-Gare B, et al. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol. 2001;28(12):2737–2743.Alarcon GS. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In: Koopman WJ, editor. Arthritis and аllied conditions. A тext book of rheumatology. Vol. 1. Baltimore, PА, London: Williams & Wilkins; 1997. pp. 679–698.Alarcon GS. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In: Koopman WJ, editor. Arthritis and аllied conditions. A тext book of rheumatology. Vol. 1. Baltimore, PА, London: Williams & Wilkins; 1997. pp. 679–698.Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584.Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584.Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. 794 р.Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. 794 р.Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi: 10.1002/1529-0131(200008)43:8<1849::aid-anr22>3.0.co;2-f.Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi: 10.1002/1529-0131(200008)43:8<1849::aid-anr22>3.0.co;2-f.Таточенко В.К., Намазова-Баранова Л.С. 13-валентная пневмококковая конъюгированная вакцина // Вопросы современной педиатрии. — 2012. — Т.11. — №2 — С. 44–47. [Tatochenko VK, Namazova-Baranova LS. 13-valent pneumococcal conjugate vaccine. Current pediatrics. 2012;11(2):44–47. (In Russ).] doi: 10.15690/vsp.v11i2.209.Таточенко В.К., Намазова-Баранова Л.С. 13-валентная пневмококковая конъюгированная вакцина // Вопросы современной педиатрии. — 2012. — Т.11. — №2 — С. 44–47. [Tatochenko VK, Namazova-Baranova LS. 13-valent pneumococcal conjugate vaccine. Current pediatrics. 2012;11(2):44–47. (In Russ).] doi: 10.15690/vsp.v11i2.209.Ко стинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. — М.: МДВ; 2009. — 252 с. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh. Moscow: MDV; 2009. 252 p. (In Russ).]Ко стинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. — М.: МДВ; 2009. — 252 с. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh. Moscow: MDV; 2009. 252 p. (In Russ).]Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–121. doi: 10.1086/313608.Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–121. doi: 10.1086/313608.chemeurope.com [Internet]. Pneumococcal conjugate vaccine [cited 2017 Jul 29]. Available from: http://www.chemeurope.com/en/encyclopedia/Pneumococcal_conjugate_vaccine.html.chemeurope.com [Internet]. Pneumococcal conjugate vaccine [cited 2017 Jul 29]. Available from: http://www.chemeurope.com/en/encyclopedia/Pneumococcal_conjugate_vaccine.html.Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23(6):485–489. doi: 10.1097/01.inf.0000129685.04847.94.Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23(6):485–489. doi: 10.1097/01.inf.0000129685.04847.94.Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341– 1348. doi: 10.1056/NEJMoa035060.Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341– 1348. doi: 10.1056/NEJMoa035060.Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139–1146. doi: 10.1016/S0140-6736(05)71876-6.Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139–1146. doi: 10.1016/S0140-6736(05)71876-6.Brenol CV, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. Rev Bras Reumatol. 2013;53(1):4–23. doi: 10.1590/S0482-50042013000100002.Brenol CV, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. Rev Bras Reumatol. 2013;53(1):4–23. doi: 10.1590/S0482-50042013000100002.Wiedermann U, Sitte HH, Burgmann H, et al. [Guidelines for vaccination of immunocompromised individuals. (In German).] Wien Klin Wochenschr. 2016;128:S337– S376. doi: 10.1007/s00508-016-1033-6.Wiedermann U, Sitte HH, Burgmann H, et al. [Guidelines for vaccination of immunocompromised individuals. (In German).] Wien Klin Wochenschr. 2016;128:S337– S376. doi: 10.1007/s00508-016-1033-6.Prelog M. Vaccination in patients with rheumatoid arthritis receiving immunotherapies. J Clin Cell Immunol. 2013;S6:007. doi: 10.4172/2155-9899.S6-007.Prelog M. Vaccination in patients with rheumatoid arthritis receiving immunotherapies. J Clin Cell Immunol. 2013;S6:007. doi: 10.4172/2155-9899.S6-007.Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ard.2011.150193.Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ard.2011.150193.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102–1106.Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102–1106.Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol. 2001;169(3):429–435. doi: 10.1677/joe.0.1690429.Sternberg EM. Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol. 2001;169(3):429–435. doi: 10.1677/joe.0.1690429.Bengtsson C, Kapetanovic MC, Kallberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010;69(10):1831–1833. doi: 10.1136/ard.2010.129908.Bengtsson C, Kapetanovic MC, Kallberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010;69(10):1831–1833. doi: 10.1136/ard.2010.129908.

The authors declare that there are no conflicts of interest present.